Peptides and Bone Health: What GH Peptides, GLP-1, and BPC-157 Mean for Osteoporosis Risk

Peptides and bone health are more connected than most clinicians discuss openly — and for women over 45, that gap in conversation carries real consequences. Peptides bone health osteoporosis is not just an emerging research topic; it is an active clinical concern that sits at the intersection of metabolic medicine, hormone biology, and skeletal integrity.

The short answer: different peptide classes affect bone in different directions. Growth hormone (GH) peptides like sermorelin and ipamorelin tend to support bone density by raising IGF-1, a direct driver of osteoblast activity. GLP-1 receptor agonists (semaglutide, tirzepatide) have a mixed signal — protective in some populations, potentially bone-negative in others, especially when rapid weight loss occurs without resistance training. BPC-157 shows meaningful bone-regenerative signals in animal studies but lacks robust human data. The evidence is nuanced. Your risk depends on which peptide you are on, your baseline bone density, your body composition trajectory, and what your labs show.

This article breaks down what we actually know — and what you need to track.

Why Bone Health Is a Metabolic Issue, Not Just an Aging Issue

Bone is not static tissue. It is a living, metabolically active organ in constant conversation with your hormones.

Osteoblasts build bone. Osteoclasts break it down. In healthy bone remodeling, these two processes stay in balance. When that balance tips — due to estrogen loss, insulin resistance, elevated cortisol, low IGF-1, or rapid weight loss — you move toward net bone loss.

Osteoporosis affects an estimated 54 million Americans over age 50, with women accounting for the majority of cases. The mechanism is hormonal from the start.

Estrogen directly suppresses osteoclast activity. When estrogen drops — during perimenopause and through menopause — osteoclasts become more active, and bone turnover accelerates. This is why women can lose up to 20% of bone density in the five to seven years following menopause. That window is exactly when most women also begin exploring GLP-1 therapy, hormone support, or peptide protocols.

The metabolic-bone connection goes further. Insulin resistance itself has been associated with altered bone quality. Chronically elevated cortisol suppresses osteoblast function. Vitamin D deficiency impairs calcium absorption from the gut. Low IGF-1 — the downstream signal of growth hormone — reduces bone formation directly.

This means your bone health is downstream of your metabolic health. That is why a metabolic clinician needs to be part of this conversation, not just an endocrinologist reviewing a DEXA scan every two years.

How the GH Axis Controls Bone Density

Growth hormone does not act on bone directly. It works through IGF-1 — insulin-like growth factor 1 — produced primarily in the liver in response to GH pulses.

IGF-1 drives osteoblast proliferation and differentiation. Research in postmenopausal women has shown that IGF-1 and its binding protein IGFBP-3 play essential roles in regulating bone metabolism. IGF-1 stimulates osteocyte proliferation and inhibits collagen degradation, promoting bone growth and development. Women with lower IGF-1 tend to have lower bone mineral density — and genetic variants in the IGF-1 gene have been linked to measurably lower BMD at the lumbar spine, femoral neck, and total hip in postmenopausal populations.

GH naturally declines with age — by roughly 15% per decade after peak in your 20s. Women experience an additional GH decline tied to estrogen loss, because estrogen directly stimulates GH secretion. Less estrogen means less GH, which means less IGF-1, which means slower bone formation.

This is where GH peptides enter the picture.

GH Peptides and Bone: What the Evidence Shows

GH secretagogues stimulate the pituitary to release its own growth hormone rather than bypassing the axis with exogenous HGH. This keeps the feedback loop intact and carries a substantially lower side effect profile.

Sermorelin is a GHRH analog — it binds to GHRH receptors in the anterior pituitary and triggers a natural GH pulse. Growth hormone deficiency is associated with osteoporosis, high cholesterol, and cardiovascular disease, and sermorelin's mechanism addresses the upstream driver by normalizing GH levels when IGF-1 is below optimal range. Sermorelin also stimulates development of bone and connective tissue — and does not suppress endogenous HGH production, unlike exogenous growth hormone.

Ipamorelin is a selective ghrelin receptor agonist. Unlike older GH secretagogues, it stimulates a clean GH spike without significantly raising cortisol or prolactin. That selectivity matters for women — elevated cortisol is independently suppressive of osteoblast function. Ipamorelin has been specifically investigated as a potential treatment for corticosteroid-induced bone loss as well as osteoporosis due to its effectiveness at boosting bone density and mineralization.

CJC-1295 paired with ipamorelin has become one of the more commonly prescribed GH peptide stacks in women's health. CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels in healthy adults with a favorable tolerability profile. The combination restores GH pulsatility without the hormonal disruption that broader-spectrum secretagogues can cause in women.

Important clinical context: GH peptides are not osteoporosis treatments. They are used within integrated metabolic and hormonal protocols. Whether they improve bone mineral density in postmenopausal women is plausible mechanistically — and clinically logical — but large randomized controlled trials specifically for this outcome do not yet exist. Use them with monitoring, not in isolation.

GLP-1 Receptor Agonists and Bone Health: A Two-Sided Story

This is where the evidence gets complicated — and where most patients using semaglutide or tirzepatide are not being given the full picture.

GLP-1 receptors are expressed in bone tissue. In theory, GLP-1 agonists could enhance bone metabolism and quality. The reality in clinical data is more mixed.

The Protective Signal

Several real-world and observational studies point toward bone benefits from GLP-1 therapy:

• A 2025 retrospective cohort study of 1,845 patients with Type 2 diabetes found that GLP-1 receptor agonists were linked to lower risks of osteoporosis compared to patients not using them. Clinical research has found that GLP-1 RAs and their analogues can significantly improve bone metabolism in diabetes patients, promoting osteoblastic differentiation.
• A large real-world analysis by EPIC Research found that among patients with osteopenia or osteoporosis, GLP-1 use was associated with a 32–38% lower fracture risk compared to matched controls not using GLP-1 drugs. This held across both patients with and without Type 2 diabetes.
• Animal model data from a 2024 systematic review found that liraglutide, a GLP-1 agonist, was capable of partially reversing osteopenia and improving bone-related parameters in both diabetic and non-diabetic osteoporosis models.

These are meaningful signals. But they do not tell the complete story.

The Bone Loss Warning

A 2024 randomized controlled trial by Hansen et al. found that 52 weeks of once-weekly semaglutide reduced hip bone mineral density by 2.6% and lumbar spine density by 2.1% compared to placebo in adults with increased fracture risk. Bone resorption markers increased while bone formation markers did not compensate — suggesting real, measurable net bone loss in high-risk individuals.

The FDA itself notes in the semaglutide label that it could increase the risk of bone fractures in older adults and women. In 2026, research presented at the American Academy of Orthopaedic Surgeons' annual meeting echoed these concerns.

A 2024 JAMA study in 195 adults with obesity over 52 weeks showed that GLP-1 therapy alone (liraglutide) led to reduced bone mineral density at the hip and spine — but that exercise plus GLP-1 therapy helped maintain bone density at the hip, spine, and forearm. The difference was resistance training.

A comprehensive review in Osteoporosis International (2025) noted that the impact of GLP-1 receptor agonists on bone health remains uncertain, particularly in the context of calorie restriction and rapid weight loss — where significant weight reduction of 7–10% through calorie restriction results in high turnover bone loss.

What This Means in Practice

The picture is this: GLP-1 drugs may protect bone in some populations — particularly those with Type 2 diabetes — while increasing bone turnover and potentially accelerating loss in older women with pre-existing osteopenia, especially those losing weight rapidly without structured resistance training.

The mechanism driving harm is likely weight loss itself, not the drug per se. Bone responds to mechanical load. When you lose significant body mass quickly, the mechanical stimulus to bone cells decreases. Less load means less signal to build.

If you are a woman over 45 on a GLP-1 protocol, bone biomarkers should be part of your monitoring panel. Not in a year. Now.

BPC-157 and Bone: What the Research Actually Supports

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It is not FDA-approved. It is widely discussed in performance and regenerative medicine circles, and the claims often outrun the evidence.

That said, the bone-specific data is more substantive than most commentary acknowledges.

Animal Studies: Strong Signal

In a 1999 landmark study by Šebečić et al., BPC-157 treatment of rabbits with segmental bone defects produced callus formation twice as large as controls after two weeks. The response was comparable to bone marrow and autologous cortical bone implantation.

A 2025 systematic review in Orthopaedic Sports Medicine screened 544 studies published between 1993 and 2024. Of 36 included studies (35 preclinical, 1 clinical), the findings showed BPC-157 helps promote healing by boosting growth factors and reducing inflammation, with improved outcomes in muscle, tendon, ligament, and bone injury models in animals.

Research in Sports Med Review describes the proposed mechanism: BPC-157 promotes osteogenesis and accelerates bone healing particularly under compromised conditions — delayed union, avascular osteonecrosis, or impaired fracture healing — by stimulating angiogenesis within bone tissue and enhancing osteoblast activity via VEGFR2-NO signaling, improving bone matrix deposition and fracture consolidation.

One mechanism worth noting: BPC-157 has been shown to upregulate growth hormone receptor expression in fibroblasts at both the mRNA and protein levels. This means it may partly amplify the effect of endogenous GH on tissues — a potentially relevant bridge between the BPC-157 and GH peptide categories.

Human Data: Still Limited

The single clinical study reviewed by the 2025 systematic review found that 7 out of 12 patients with chronic knee pain felt relief for over six months following one BPC-157 injection. That is not bone density data — and it is a very small sample.

There are currently no large-scale human trials on BPC-157 and bone mineral density. The animal data is promising. The translational leap is still being made. Until that gap closes, BPC-157 should not be used as a primary treatment for osteoporosis, and anyone recommending it as such is working ahead of the evidence.

BPC-157 and Regulatory Status

BPC-157 is not FDA-approved and falls into a regulatory gray area, particularly when promoted as a supplement or administered outside of clinical oversight. The FDA issued warnings about compounded BPC-157 products in 2024. If you are considering this peptide, that conversation belongs with a physician — not an online marketplace.

Peptide Comparison: Bone Health at a Glance

What Bone Biomarkers Should You Be Tracking?

If you are on any peptide protocol — or approaching or in menopause — this panel is not optional. It is foundational.

Essential Bone Biomarkers

1. DEXA Scan (Dual-Energy X-Ray Absorptiometry) The gold standard for measuring bone mineral density. Reports a T-score. Below −1.0 is osteopenia. Below −2.5 is osteoporosis. Baseline before starting any significant hormonal or metabolic protocol, then annually.

2. Serum P1NP (Procollagen Type 1 N-terminal Propeptide) A bone formation marker. Released when collagen is being assembled in new bone. The International Osteoporosis Foundation and the European Calcified Tissue Society have identified P1NP and CTX-1 as the reference markers for monitoring osteoporosis treatment response. P1NP is the preferred formation marker in clinical practice.

3. Serum CTX (Beta-CrossLaps / C-Telopeptide of Type I Collagen) A bone resorption marker. Elevated CTX means osteoclasts are actively breaking down bone matrix. High CTX in the context of GLP-1 therapy or rapid weight loss is a clear signal for intervention. Postmenopausal women typically have higher CTX ranges (0.15–0.70 μg/L) due to accelerated bone turnover. Both CTX and P1NP samples should be collected fasting in the early morning, as bone turnover markers show significant diurnal variation.

4. 25-Hydroxyvitamin D (25-OH-D) Vitamin D deficiency impairs calcium absorption from the gut. Without adequate vitamin D, even a calcium-rich diet cannot fully protect your bones. Target 40–60 ng/mL for bone protection. Vitamin D deficiency is widespread even in women who spend time outdoors.

5. Serum Calcium and PTH (Parathyroid Hormone) PTH regulates calcium homeostasis. Elevated PTH drives osteoclast activity and bone resorption. Chronically low calcium or vitamin D causes compensatory PTH rise — and accelerated bone loss.

6. IGF-1 Particularly relevant if you are on GH peptides. Tracks GH axis activity and correlates with anabolic signaling to bone. Should be monitored on any sermorelin or ipamorelin protocol.

7. Estradiol The most undertracked bone-protective hormone in women over 45. Estrogen directly suppresses osteoclast activity. Low estradiol — even without clear menopause symptoms — can accelerate bone turnover silently.

Monitoring Frequency

Clinical Strategies to Protect Bone During Peptide Protocols

These are not optional additions. They are the difference between a protocol that preserves your skeleton and one that silently erodes it.

1. Resistance training — non-negotiable. Mechanical loading is the primary stimulus for osteoblast activity. The 2024 JAMA study showed that exercise combined with GLP-1 therapy preserved bone density that GLP-1 therapy alone reduced. Aim for two to three sessions per week of progressive resistance training targeting major muscle groups.

2. Pace weight loss deliberately. Rapid weight loss — more than 1–2 lbs per week over extended periods — accelerates bone resorption independent of the drug used. Slower, structured loss with adequate protein intake preserves lean mass and protects bone.

3. Optimize vitamin D and calcium intake. Target 1,000–1,200 mg of calcium daily through diet (dairy, leafy greens, fortified foods) and supplementation as needed. Vitamin D at 2,000–4,000 IU daily is reasonable for most women over 45 on an active metabolic protocol, adjusted based on serum 25-OH-D levels.

4. Prioritize dietary protein. Amino acids from dietary protein are substrates for collagen synthesis in bone. Women on GLP-1 therapy who are significantly restricting food intake often fall short on protein. Aim for 1.2–1.6 g/kg of body weight daily.

5. Discuss hormone support with your clinician. If estradiol is low and bone turnover markers are elevated, peptide protocols alone will not be sufficient. Hormone therapy — including estrogen and progesterone as appropriate — remains one of the most evidence-based interventions for bone preservation in perimenopausal and menopausal women.

The Takeaway: Peptides, Bone Health, and Osteoporosis Risk

Here is the clinical summary:

• GH peptides (sermorelin, ipamorelin) support bone through IGF-1 upregulation and direct stimulation of bone development. They are not primary osteoporosis treatments, but they are mechanistically supportive and warranted in women with low IGF-1 on integrated metabolic protocols.
• GLP-1 receptor agonists carry a dual signal on bone. They may protect in some populations — particularly those with Type 2 diabetes — but can drive bone turnover and decrease BMD in older women, especially during rapid weight loss without resistance training. The FDA has flagged this risk on the semaglutide label.
• BPC-157 shows compelling bone-regenerative signals in animal models and upregulates GH receptor expression in connective tissue. It lacks human trial data for bone mineral density. It is not a substitute for established osteoporosis interventions.
• Monitoring matters more than the peptide. Your bone biomarker panel — CTX, P1NP, vitamin D, IGF-1, estradiol — tells you what is actually happening. A DEXA scan confirms structural integrity. Without these, you are guessing.

Peptide therapy for women over 45 is a legitimate and growing field. But bone health is a quiet casualty when protocols are built without metabolic oversight. The conversation about peptides, bone health, and osteoporosis risk needs to happen at the start of any protocol — not after a fracture.

Take Action With Your Meto Clinician

If you are on a GLP-1, GH peptide, or any active metabolic or hormonal protocol, ask your clinician about including bone biomarkers in your next metabolic panel.

Meto's clinical team works with women navigating perimenopause, menopause, hormonal health, and metabolic syndrome — the conditions most directly tied to bone loss risk. A Comprehensive Metabolic Panel is a strong starting point. Your clinician can advise on adding bone-specific markers based on your current protocol and history.

Don't wait for a fracture to start tracking. Book a session and ask about bone biomarkers today.

Get Care Today →

Frequently Asked Questions

Can peptides help treat osteoporosis?

No peptide currently has FDA approval for treating osteoporosis, with the exception of calcitonin, a naturally occurring peptide hormone used in specific clinical contexts. GH secretagogues like sermorelin and ipamorelin support bone formation through IGF-1, and BPC-157 shows osteogenic signals in animal models. These peptides can be part of a bone-supportive metabolic protocol, but they should not replace established osteoporosis treatments such as bisphosphonates, denosumab, or hormone therapy where indicated.

Does semaglutide (Ozempic/Wegovy) cause bone loss?

The evidence is mixed. A 2024 randomized controlled trial found that 52 weeks of semaglutide reduced hip and lumbar spine bone mineral density in adults with increased fracture risk. However, real-world data has also associated GLP-1 use with lower fracture risk in patients with Type 2 diabetes and pre-existing bone density disorders. The key variable is weight loss pace and whether resistance training is incorporated. The FDA has noted potential increased fracture risk in older adults and women on the semaglutide label.

What blood tests should women on peptide protocols get for bone health?

At minimum: serum CTX (bone resorption marker), P1NP (bone formation marker), 25-hydroxyvitamin D, calcium, PTH, IGF-1, and estradiol. These, combined with a baseline DEXA scan, give a complete picture of bone metabolism. The International Osteoporosis Foundation recommends P1NP and CTX as the reference markers for monitoring bone health. Samples for CTX and P1NP should be collected fasting in the early morning for accuracy.

How does menopause affect bone health and peptide response?

Estrogen directly suppresses osteoclast activity. When estrogen declines at menopause, osteoclasts become more active and bone turnover accelerates — women can lose up to 20% of bone density in the 5–7 years following menopause. This same window coincides with declining growth hormone and IGF-1 due to the estrogen-GH relationship. GH peptides can partially address the IGF-1 decline, but they do not replace estrogen's protective effects on bone. Women in this window need both metabolic and hormonal evaluation.

Is BPC-157 safe to use for bone regeneration?

BPC-157 is not FDA-approved and exists in a regulatory gray area. Animal studies consistently show osteogenic effects — including callus formation comparable to bone marrow grafts in some models — but there are currently no large-scale human trials for bone mineral density outcomes. Animal studies show no toxic effects at studied doses, but clinical safety data in humans is extremely limited. Any use of BPC-157 should be under physician supervision, and it should not be purchased from unregulated online sources.

Can I be on a GLP-1 and protect my bones at the same time?

Yes — and the evidence points clearly to how. Combining GLP-1 therapy with progressive resistance training preserves bone density that GLP-1 alone can reduce. A 2024 JAMA study demonstrated this directly. Additionally, ensuring adequate protein intake (1.2–1.6 g/kg daily), optimizing vitamin D levels, avoiding excessively rapid weight loss, and monitoring bone turnover markers every 3–6 months are all actionable steps that significantly reduce bone loss risk while on GLP-1 therapy.